Clinical trial
A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic…
NCT01904292 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT01904292 |
|---|---|
| Title | A Study of Subcutaneously Administered Tocilizumab in Participants With Systemic Juvenile Idiopathic Arthritis |
| Official title | A Phase Ib, Open-Label, Multicenter Study to Investigate the Pharmacokinetics, Pharmacodynamics, and Safety of Tocilizumab Following Subcutaneous Administration to Patients With Systemic Juvenile Idiopathic Arthritis |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Juvenile Idiopathic Arthritis |
| Intervention type | Drug |
| Interventions | Tocilizumab |
| Enrollment | 52 |
| Start date | Aug 15, 2013 |
| Primary completion | Jun 13, 2017 |
| Completion | Jun 13, 2017 |
| First posted | Jul 22, 2013 |
| Last update posted | Nov 20, 2017 |
| Countries | Argentina, Australia, Brazil, Canada, France, Germany, Italy, Mexico, Russia, Spain, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: